Greater fear of hypoglycaemia with premixed insulin thanwith basal-bolus insulin glargine and glulisine: Patient-reported outcomes from a 60-week randomisedstudy

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1121-1127

  Polonsky, W H ^a   Thompson, S ^b   Wei, W ^b   Riddle, M C ^c   Chaudhari, S ^d   Jackson, J ^d   Bruno, A S ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d XCENDA   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Clinical trial; Diabetes mellitus; Insulin analogues; Insulin therapy; Randomised trial; Type 2 diabetes

Indexed keywords

INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; INSULIN; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; ANALOGS AND DERIVATIVES; ANXIETY; BLOOD; BODY MASS; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PSYCHOLOGY; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRES; UNITED STATES;

EID: 84914159346     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12328     Document Type: Article

References (21)

1. Peyrot M, Rubin RR, Polonsky WH, Best JH. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr Med Res Opin 2010; 26: 1047-1054.
2. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 2003; 20: 626-634.
3. Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectr 2000; 13: 36-41.
4. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007; 68: 10-15.
5. Lee LJ, Fahrbach JL, Nelson LM et al. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the DURABLE trial. Diabetes Res Clin Pract 2010; 89: 157-166.
6. Peyrot M, Rubin RR, Chen X, Frias JP. Associations between improved glucose control and patient-reported outcomes after initiation of insulin pump therapy in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 471-476.
7. Bradley C, Gilbride CJ. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes Metab 2008; 10(Suppl. 2): 50-65.
8. Riddle MC, Rosenstock J, Vlajnic A, Gao L. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014; 16: 396-402.
9. Derogatis LR. The psychosocial adjustment to illness scale (PAIS). J Psychosom Res 1986; 30: 77-91.
10. Cheung YB, Thumboo J, Gao F et al. Mapping the English and Chinese Versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D Utility Index. Value Health 2009; 12: 371-376.
11. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
12. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17: 267-274.
13. Secnik Boye K, Matza LS, Oglesby A et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006; 4: 80.
14. Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30: 795-800.
15. Swinnen SG, Dain MP, Aronson R et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010; 33: 1176-1178.
16. Hajos TR, Pouwer F, de Grooth R et al. Initiation of insulin glargine in patients with type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet Med 2011; 28: 1096-1102.
17. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-the glargine and aspart study (GLASS). A randomised cross-over study. Diabetes Res Clin Pract 2007; 77: 215-222.
18. Brod M, Cobden D, Lammert M, Bushnell D, Raskin P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007; 5: 8.
19. Bradley C, El-Haschimi K. Treatment satisfaction in patients with type 2 diabetes: basal insulin plus oral agents versus twice-daily premixed insulin alone-analyses by country. Diabet Med 2006; 23(Suppl. 1): 361(P1010).
20. Wolffenbuttel BH, van Ouwerkerk BM, Veldhuyzen BF, Geelhoed-Duijvestijn PH, Jakobsen G, van Doorn LG. Comparative effects of two different multiple injection regimens on blood glucose control and patient acceptance in type 1 diabetes. Diabet Med 1990; 7: 695-699.
21. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.